Summary of Dogwood Therapeutics Special Meeting Company Overview - Company: Dogwood Therapeutics (NasdaqCM:DWTX) - Event: 2025 Extraordinary General Meeting - Date: November 21, 2025 Key Proposals Discussed 1. Proposal One: Approval for the issuance of common stock upon conversion of Series A non-voting convertible preferred stock, par value $0.0001 per share [8] 2. Proposal Two: Approval for the issuance of common stock upon conversion of Series A1 non-voting preferred stock, par value $0.0001 per share [9] 3. Proposal Three: Approval for the issuance of common stock upon conversion of Series A2 non-voting convertible preferred stock, par value $0.0001 per share [9] 4. Proposal Four: Approval of the Dogwood Therapeutics Second Amended and Restated 2020 Equity Incentive Plan [9] 5. Proposal Five: Approval for the adjournment of the special meeting to a later date if necessary [9] Voting Results - Proposal One: Approved under both Delaware law and NASDAQ Listing Rules [13] - Proposal Two: Approved under both Delaware law and NASDAQ Listing Rules [13] - Proposal Three: Approved under both Delaware law and NASDAQ Listing Rules [14] - Proposal Four: Approved [14] - Proposal Five: Approved [14] Additional Information - A quorum was established with more than one-third of the outstanding shares present [6] - The final voting results will be filed with the SEC on Form 8K within four business days after the meeting [16] - The meeting concluded with a focus on improving care for patients suffering from pain and neuropathy [16]
Dogwood Therapeutics (NasdaqCM:DWTX) 2025 Extraordinary General Meeting Transcript